Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients with primary malignant tumors of the central nervous system (CNS) excluding subjects with primary CNS lymphoma.~2. Age\> 21 years.~3. There should be a gap of two weeks between the last surgery and/or radiotherapy procedure and the day of randomization. If the procedure were intrabdominal, the gap should be of four weeks.~4. Patients with neutrophils\> 1.5 x 109 / L and platelets\> 100 x 109 / L.~5. Signed written informed consent for participation in the trial.~Exclusion Criteria:~1. Known hypersensitivity to Temozolomide or any other ingredient of the pharmaceutical formulation.~2. Any situation (eg. vomiting) that may interfere with the absorption of the product under study.~3. Chemotherapy or biological therapy within four weeks prior to administering the products under study.~4. Patients who experience any symptoms of toxicity to prior antineoplastic therapies upon administration of the products under study.~5. Participation in other clinical research studies during the 90 days before the start of this study.~6. History of alcohol or drugs abuse.~7. History of severe allergic reactions to any type of antigen.~8. History of gastrointestinal surgery (except uncomplicated appendectomy, of at least three months old).~9. Patients whose clinical status would affect the safety of the products under study or interfere with the pharmacokinetic evaluation, at the discretion of the investigator.~10. Pregnant women or women planning to become pregnant during the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temodal (Type: ACTIVE_COMPARATOR): Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
- Dralitem (Type: EXPERIMENTAL): Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).